Clinical trials: Oral Cancer
Neoplasms, NUT Carcinoma
BI 894999 First in Human Dose Finding Study in Advanced Malignancies
This study is open to adults with different types of advanced cancer (solid tumours). The study is also open to patients with diffuse large B-cell lymphoma in whom previous treatment was not successful.
- Trial name
- NCT02516553
- Testing
- BI 894999
- Where
- 16 sites in United States, Belgium and 4 more
- Volunteers
- 174 people
- Sponsor
- Boehringer Ingelheim
Tumors Characterized by Genetic Abnormalities of ALK
A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase
This study assessed the safety and efficacy of LDK378 in adult patients with genetic abnormalities in anaplastic lymphoma kinase (ALK).
- Trial name
- NCT01283516
- Testing
- LDK378
- Where
- 21 sites in United States, Australia and 9 more
- Volunteers
- 304 people
- Sponsor
- Novartis Pharmaceuticals
Hormone Receptor Positive Breast Carcinoma, HER2-negative Breast Cancer
A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
This clinical trial is a Phase I dose escalation and dose expansion and Phase II monotherapy open-label, first-in-human, multicenter study of OP-1250 in adult subjects with advanced and/or metastatic hormone receptor…
- Trial name
- NCT04505826
- Testing
- OP-1250
- Where
- 19 sites in United States, Australia
- Volunteers
- 153 people
- Sponsor
- Olema Pharmaceuticals, Inc.
Medullary Thyroid Cancer, Infantile Myofibromatosis
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
This is an open-label, multi-center Phase 1/2 study of oral LOXO-292 in pediatric participants with an activating rearranged during transfection (RET) alteration and an advanced solid or primary CNS tumor.
- Conditions
- Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer
- Trial name
- LIBRETTO-121 (NCT03899792)
- Testing
- Selpercatinib
- Where
- 26 sites in United States, Australia and 9 more
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Pain, Neoplasms
CORAL XT - Open-label Extension Trial of the CORAL Trial
The purpose of this trial was to find out how well cebranopadol is tolerated and how often, and which, adverse reactions occur when it is taken every day for a longer period of time.
- Conditions
- Pain, Neoplasms, Chronic Pain
- Trial name
- CORAL XT (NCT02031432)
- Testing
- Cebranopadol
- Where
- 22 sites in Austria, Belgium and 8 more
- Volunteers
- 76 people
- Sponsor
- Tris Pharma, Inc.
Carcinoma, Non-Small-Cell Lung
Nintedanib and Weekly Docetaxel in Lung Adenocarcinoma
Phase I study. To determine the MTD (Maximum Tolerated Dose) of nintedanib + weekly Docetaxel in patients with locally advanced or metastatic lung adenocarcinoma after failure of platinum-based first line chemotherapy.
- Trial name
- NCT02668393
- Testing
- Docetaxel, Nintedanib
- Where
- 4 sites in France, Germany
- Volunteers
- 14 people
- Sponsor
- Boehringer Ingelheim
Carcinoma, Non-Small-Cell Lung
Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
Study to evaluate the efficacy and safety of capmatinib as a single-agent treatment for subjects with advanced/metastatic (stage IIIB or IV) non-small cell lung cancer (NSCLC) who had wild-type epidermal growth factor receptor…
- Trial name
- NCT02414139
- Testing
- Capmatinib
- Where
- 95 sites in United States, Argentina and 18 more
- Volunteers
- 373 people
- Sponsor
- Novartis Pharmaceuticals
Basal Cell Carcinoma
A Study of Vismodegib With Surgery in Participants With Previously Untreated Basal Cell Carcinoma
This randomized, double-blind, placebo-controlled study will assess the efficacy and safety of vismodegib with surgery in participants with basal cell carcinoma.
- Trial name
- NCT01898598
- Testing
- Vismodegib
- Where
- 21 sites in United States
- Volunteers
- 18 people
- Sponsor
- Hoffmann-La Roche
Pain
An Efficacy and Safety Study of Oral Osmotic Therapeutic System (OROS) Hydromorphone Hydrochloride (HCl) in Participants With Cancer Related Pain
The purpose of this study is to compare the safety and efficacy of Oral Osmotic Therapeutic System (OROS) hydromorphone hydrochloride (HCl) with controlled-release oxycodone HCl in participants with cancer-related pain.
- Trial name
- NCT01205126
- Testing
- Hydromorphone HCl, Oxycodone HCl CR
- Where
- 12 sites in China
- Volunteers
- 260 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Mucositis, Solid Tumors
Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer
The purpose of this research study is to test the safety and effectiveness of palifermin to determine if weekly doses can be safely administered to reduce the incidence (occurrence of), duration (length of time) and severity…
- Conditions
- Mucositis, Solid Tumors, Stomatitis, Head and Neck Cancer
- Trial name
- NCT00101582
- Testing
- palifermin, cisplatin chemotherapy, Radiotherapy
- Volunteers
- 188 people
- Sponsor
- Swedish Orphan Biovitrum
Carcinoma, Hepatocellular
Dose Escalation Study of Nintedanib (BIBF 1120) in Japanese Patients With Hepatocellular Carcinoma
The aim of the study is to investigate the safety, tolerability, efficacy and pharmacokinetics (PK) for Japanese hepatocellular carcinoma which are not amenable to curative surgery or loco regional therapy
- Trial name
- NCT01594125
- Testing
- Nintedanib high dose, Nintedanib low dose, Nintedanib medium dose
- Where
- 5 sites in Japan
- Volunteers
- 30 people
- Sponsor
- Boehringer Ingelheim
Prostate Cancer, Endometriosis
A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Healthy Subjects
This is a nonrandomized, open-label, fixed-sequence, 2-arm study designed to assess the effect of multiple doses of fluconazole or atorvastatin on the single-dose pharmacokinetics of TAK-385 in healthy adult subjects.
- Trial name
- NCT02093390
- Testing
- TAK-385, Fluconazole, Atorvastatin
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Millennium Pharmaceuticals, Inc.
Multiple Myeloma
Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma
This study will evaluate the efficacy and safety of LBH589B in adult patients with multiple myeloma who have received at least two prior therapies and are refractory to their last therapy.
- Trial name
- NCT00445068
- Testing
- LBH589
- Where
- 29 sites in United States, Germany
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Medulloblastoma
A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)
This Phase II study evaluated the safety and efficacy of LDE225 in adult and pediatric patients with Hh-pathway activated, relapsed MB.
- Trial name
- NCT01708174
- Testing
- LDE225, TMZ
- Where
- 41 sites in United States, Australia and 11 more
- Volunteers
- 22 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)
A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer
The purpose of this clinical study is to establish the safety profile, determine the maximum tolerated dose (MTD) and recommend a Phase 2 dose and schedule of SRA737; and to evaluate the efficacy of SRA737 in…
- Trial name
- NCT02797964
- Testing
- SRA737
- Where
- 15 sites in United Kingdom
- Volunteers
- 107 people
- Sponsor
- Sierra Oncology LLC - a GSK company
Malignant Melanoma, Neoplasms
A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)
This open-label, multi-center, three-period, one-sequence study will investigate the effect of rifampin on the PK of vemurafenib in participants with unresectable BRAFV600-mutation positive metastatic melanoma or other malignant…
- Trial name
- NCT01765543
- Testing
- Rifampin, Vemurafenib
- Where
- 15 sites in United States, Brazil and 3 more
- Volunteers
- 27 people
- Sponsor
- Hoffmann-La Roche
Advanced or Inoperable Gastric Cancer
Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer
This study enrolled participants with previously-treated advanced or inoperable gastric cancer who have responded to first line platinum therapy into two treatment arms.
- Trial name
- NCT03427814
- Testing
- Pamiparib
- Where
- 65 sites in United States, Australia and 14 more
- Volunteers
- 136 people
- Sponsor
- BeiGene
Psoriasis
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01163253
- Testing
- CP-690,550
- Where
- 323 sites in United States, Argentina and 34 more
- Volunteers
- 2,867 people
- Sponsor
- Pfizer
Classical Hodgkin's Lymphoma
Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma
This study evaluated the efficacy of oral panobinostat in participants with refractory/relapsed classical Hodgkins lymphoma (HL) who have received prior treatment with high dose chemotherapy and autologous stem cell transplant.
- Trial name
- NCT00742027
- Testing
- Panobinostat
- Where
- 46 sites in United States, Australia and 11 more
- Volunteers
- 129 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Endometrial Cancer
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
This is a prospective multi-center, open-label, single arm, Phase II study to investigate the safety and efficacy of BKM120 in patients with advanced endometrial carcinoma whose disease progressed on or after a first-line…
- Trial name
- NCT01289041
- Testing
- BKM120
- Where
- 42 sites in United States, Australia and 11 more
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals